- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04479514
Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Study Overview
Status
Detailed Description
This prospective, single-arm phase 2 clinical trial is looking at whether gentle skin care, sun protection and dilute bleach baths might decrease the chances or the severity of skin changes that occur during treatment for brain tumors.
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.
Participants will receive a study treatment regimen that involves a daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study.
Participants enrolled in this study, will be in this research study during the course of their anti-cancer treatment and receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of anti-cancer treatment, and at twelve weeks after the start of anti-cancer treatment.
Participants will be followed for twelve weeks.
It is expected that about 20 people will take part in this research study.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jennifer Huang, MD
- Phone Number: 617-355-1477
- Email: Jennifer.Huang@childrens.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Diagnosed with a brain tumor between ages 6 months old -18 years old and will undergo treatment with at least one of the following:
- Targeted BRAF inhibitor therapy to treat the brain tumor
- Targeted MEK inhibitor therapy to treat the brain tumor
- Targeted pan-RAF inhibitor therapy to treat the brain tumor
- Subjects may participate in other studies, including therapeutic trials.
- Ability to comply with PSCR including sun protection, gentle skin care and every other day dilute bleach baths.
- Ability to understand and/or the willingness of their parent or legally authorized representative to sign a written informed consent document.
Exclusion Criteria:
- Diagnosed with brain tumor at > 18 years old
- No data in medical records regarding treatment exposures
- Treated with a BRAF, MEK or pan-RAF inhibitor in the last three months
- Past or present allergic reaction to bleach
- Past or present allergic reactions to sunscreen and/or creams, lotions, emollients to be utilized in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Preventative Skin Care Routine
Participants will perform a preventative skin care routine that includes daily sun protection, daily gentle skin care and every-other-day dilute bleach baths for the duration of the study. Participants will receive skin examinations and complete a survey about their skin condition at the initial visit when anti-cancer treatment is started, at six weeks after the start of treatment, and at twelve weeks after the start of treatment. |
Daily warm baths or showers
moisturizers applied daily immediately after bathing
Mineral based sunscreen of SPF 30 or higher applied on a daily basis on all sun exposed areas.
Other Names:
Sun protective clothing worn when outdoors
Limit sun exposure during peak hours of 10am-4pm
Warm 10-15 minute dilute bleach baths every other day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Cutaneous Reaction
Time Frame: 12 weeks
|
Proportion (percentage) of patients with one or more cutaneous reaction to targeted BRAF, MEK, or Pan-RAF inhibitor therapy
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Cutaneous Reaction Severity
Time Frame: 12 weeks
|
Measured by the Common Terminology Criteria for Adverse Events (CTCAE)
|
12 weeks
|
Xerosis Severity
Time Frame: 12 weeks
|
Measured by the Overall Dry Skin Score (ODS)
|
12 weeks
|
Hand foot syndrome Severity
Time Frame: 12 weeks
|
Measured by the Hand-Foot Skin Reaction and Quality of Life Score (HFS-14)
|
12 weeks
|
Pediatric Quality of life
Time Frame: 12 weeks
|
Pediatric Quality of Life Inventory (PedsQL)
|
12 weeks
|
Children's Dermatology Quality of life
Time Frame: 12 weeks
|
Children's Dermatology Life Quality Index (CDLQI)
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jennifer Huang, MD, Boston Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19-579
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pediatric Cancer
-
Emory UniversityNational Cancer Institute (NCI)Recruiting
-
Ann & Robert H Lurie Children's Hospital of ChicagoSilicon Valley Community FoundationUnknownCancer | Pediatric CancerUnited States
-
University of BirminghamCompletedCancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AMLUnited Kingdom, Australia, Netherlands
-
University of California, San DiegoNational Cancer Institute (NCI); Dana-Farber Cancer Institute; University of... and other collaboratorsNot yet recruiting
-
Immune Oncology Research InstituteRecruitingContinuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With DexamethasonePediatric CancerArmenia
-
Connecticut Children's Medical CenterThe Hospital for Sick ChildrenRecruitingPediatric CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingPediatric CancerUnited States
-
Erin RowellRecruiting
-
Giselle ShollerRecruiting
-
Rigshospitalet, DenmarkUniversity of Copenhagen; Danish Cancer Society; Danish Child Cancer FoundationRecruitingPediatric CancerDenmark
Clinical Trials on Warm Baths or Showers
-
Cathay General HospitalNot yet recruitingPreoperative Anxiety
-
Washington University School of MedicineCompletedThe Natural History of Community-Associated MRSA Infections and Decolonization Strategies (StLStaRS)Furunculosis | Staphylococcus Aureus | Staphylococcal Skin Infections | AbscessesUnited States
-
University of PittsburghThe Grable Foundation; The Shear Family Foundation; Heinz EndowmentsRecruitingParenting | Child Development | Child Behavior Problem | Parent Child Abuse | Child LanguageUnited States